Business Description
Founded in 2014 and based in San Diego, California, Dermata Therapeutics is a late-stage pharmaceutical company working to bring new treatments to market for skin conditions and aesthetic concerns. Its primary drug candidate, XYNGARI, is currently in Phase 3 trials for moderate-to-severe acne and has shown early promise in treating mild-to-moderate psoriasis. The company is also advancing DMT410, which has completed early-stage trials for excessive underarm sweating and cosmetic skin applications, and has partnered with Revance Therapeutics to study how XYNGARI performs alongside DAXXIFY, Revance's botulinum toxin product.
